| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 5, 2015El dispositivo de 16 contactos y batería desechable de alta capacidad más pequeña del mundo expande la oferta del sistema de estimulación de la médula espinal
Boston Scientific anuncia la comercialización del sistema Precision Novi™ para la estimulación de la médula espinal (EME) en la Sociedad Internacional de Neuromodulación en Montreal,...
-
Mar 13, 2015Un dispositivo innovador que ofrece una alternativa al tratamiento con warfarina a largo plazo para reducir el riesgo de ictus en los pacientes con fibrilación auricular no valvular.
Boston Scientific Corporation (NYSE: BSX) ha recibido la aprobación de su dispositivo WATCHMAN para el cierre de la orejuela auricular izquierda por parte de la Administración de alimentos y...
-
Sep 18, 2014Vercise DBS System is the First DBS System Offering Precise Neural Targeting and a 25-Year Battery Life
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement...
-
Jun 14, 2014
Un video, resumen el congreso EuroPCR, que incluye los últimos resultados de los estudios clínicos EVOLVE y REPRISE II presentados por Dr. Kieth Oldroyd y Dr Daniel Blackman. Exención de...
-
Jun 12, 2014Data Presented at the 18th International Congress of Parkinson's Disease and Movement Disorders Demonstrate Highly Significant Improvement in Motor Function for Patients with Parkinson's Disease
Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent...
-
Jun 11, 2014Data Presented at the International Congress of Parkinson's Disease and Movement Disorders Demonstrate Superior Therapeutic Window for the Treatment of Parkinson's Disease
A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System for the treatment of...
-
May 22, 2014Los datos del estudio EVOLVE, presentados hoy en EuroPCR 2014, muestran además un excelente perfil de seguridad.
Boston Scientific Corporation (NYSE: BSX) ha anunciado datos de seguimiento a los tres años del estudio clínico EVOLVE, en el que se comparan la eficacia y el rendimiento del stent coronario...
-
Apr 11, 2014Study to Evaluate Clinical Outcomes and Economic Value of the Vercise™ Deep Brain Stimulation (DBS) System
Boston Scientific Corporation (NYSE: BSX) has enrolled the first patient in a new registry to evaluate clinical outcomes and the economic value of the Vercise™ Deep Brain Stimulation (DBS)...
-
Apr 2, 2014Demonstrating design leadership in drug eluting stent (DES) technology, Boston Scientific released new data that continue to reinforce the advantages of platinum chromium stents.
Data from the PLATINUM Workhorse clinical trial were presented by Dean Kereiakes, M.D., F.A.C.C., The Christ Hospital Heart and Vascular Center, Cincinnati, Ohio. The trial compared the safety and...